NEW YORK (GenomeWeb News) – DxTerity Diagnostics today said that the Scottsdale Clinical Research Institute in Arizona will use the firm’s Quenched Auto Ligating reagents for development of a microRNA-based cardiac test.
The test will measure the expression of a microRNA biomarker in heart biopsy tissue samples, which has been shown to correlate with post-operative heart arrhythmia. DxTerity said that SCRI will use its QUAL reagents to validate the biomarker’s ability to reveal at-risk patients before an arrhythmia strikes.